Furthermore, a prespecified subgroup analysis of HF individuals from the SELECT trial evaluating the effects of semaglutide on cardiovascular outcomes in people with overweight or obesity, which included 2,273 HFpEF and 1,347 HFrEF patients, showed that the therapy was associated with a reduction in the HF composite outcome (cardiovascular death or HF hospitalisation/emergency visit) across LVEF, suggesting that GLP-1 RAs may improve outcomes at least in obese HF patients regardless of diabetes status
If heart failure occurs, dosage reduction or discontinuation of the TZD must be considered
2 Los agonistas del receptor GLP-1, tambin conocidos como anlogos de GLP-1, son medicamentos que ayudan a controlar los niveles de azcar en sangre en personas con diabetes tipo 2
1 And theyre having a significant effect on the aesthetic and functional aspects of the face, said Joseph, who has observed a striking rise in patients presenting with sudden midface collapse, deepened tear troughs, and prominent orbital rims
minimum, 2 weeks, maximum, 40 weeks)
Special attention needs to be given to populations in which hypoglycaemia is most dangerous, for example people with frailty, in whom agents without risk of hypoglycaemia need to be prioritised
